Ultragenyx Pharmaceutical (RARE) Competitors

Ultragenyx Pharmaceutical logo
$16.48 -0.74 (-4.27%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$16.66 +0.18 (+1.06%)
As of 11/20/2026 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RARE vs. IBRX, LGND, CGON, MIRM, and GRFS

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? Ultragenyx Pharmaceutical's main competitors and comparable companies include ImmunityBio (IBRX), Ligand Pharmaceuticals (LGND), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), and Grifols (GRFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ultragenyx Pharmaceutical compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

ImmunityBio currently has a consensus price target of $16.00, indicating a potential upside of 166.00%. Ultragenyx Pharmaceutical has a consensus price target of $29.79, indicating a potential upside of 80.71%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts clearly believe ImmunityBio is more favorable than Ultragenyx Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

Ultragenyx Pharmaceutical has a net margin of -71.78% compared to ImmunityBio's net margin of -607.79%.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-607.79% N/A -54.83%
Ultragenyx Pharmaceutical -71.78%N/A -39.70%

In the previous week, ImmunityBio had 1 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 7 mentions for ImmunityBio and 6 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.34 beat ImmunityBio's score of 0.06 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
0 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ultragenyx Pharmaceutical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ImmunityBio has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. ImmunityBio is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M56.48-$351.40M-$1.08N/A
Ultragenyx Pharmaceutical$673M2.50-$575M-$5.19N/A

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ImmunityBio has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Summary

Ultragenyx Pharmaceutical beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Ligand Pharmaceuticals currently has a consensus price target of $355.38, suggesting a potential upside of 23.88%. Ultragenyx Pharmaceutical has a consensus price target of $29.79, suggesting a potential upside of 80.71%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

Ligand Pharmaceuticals has a net margin of 20.27% compared to Ultragenyx Pharmaceutical's net margin of -71.78%. Ligand Pharmaceuticals' return on equity of 5.22% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals20.27% 5.22% 2.74%
Ultragenyx Pharmaceutical -71.78%N/A -39.70%

In the previous week, Ligand Pharmaceuticals had 8 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 14 mentions for Ligand Pharmaceuticals and 6 mentions for Ultragenyx Pharmaceutical. Ligand Pharmaceuticals' average media sentiment score of 0.47 beat Ultragenyx Pharmaceutical's score of 0.34 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ultragenyx Pharmaceutical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$268.09M21.40$124.45M$2.24128.07
Ultragenyx Pharmaceutical$673M2.50-$575M-$5.19N/A

Ligand Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Summary

Ligand Pharmaceuticals beats Ultragenyx Pharmaceutical on 12 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Ultragenyx Pharmaceutical has a net margin of -71.78% compared to CG Oncology's net margin of -3,851.09%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat CG Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
CG Oncology-3,851.09% -24.58% -23.40%
Ultragenyx Pharmaceutical -71.78%N/A -39.70%

In the previous week, CG Oncology had 39 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 45 mentions for CG Oncology and 6 mentions for Ultragenyx Pharmaceutical. CG Oncology's average media sentiment score of 0.73 beat Ultragenyx Pharmaceutical's score of 0.34 indicating that CG Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CG Oncology
15 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Ultragenyx Pharmaceutical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CG Oncology has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. CG Oncology is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CG Oncology$4.04M1,757.00-$160.99M-$2.76N/A
Ultragenyx Pharmaceutical$673M2.50-$575M-$5.19N/A

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CG Oncology currently has a consensus target price of $102.22, indicating a potential upside of 28.63%. Ultragenyx Pharmaceutical has a consensus target price of $29.79, indicating a potential upside of 80.71%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

CG Oncology has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Summary

Ultragenyx Pharmaceutical beats CG Oncology on 10 of the 17 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 5 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.58 beat Ultragenyx Pharmaceutical's score of 0.34 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mirum Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ultragenyx Pharmaceutical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ultragenyx Pharmaceutical has a net margin of -71.78% compared to Mirum Pharmaceuticals' net margin of -134.75%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mirum Pharmaceuticals-134.75% -97.25% -12.59%
Ultragenyx Pharmaceutical -71.78%N/A -39.70%

Mirum Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Mirum Pharmaceuticals presently has a consensus price target of $155.56, indicating a potential upside of 61.83%. Ultragenyx Pharmaceutical has a consensus price target of $29.79, indicating a potential upside of 80.71%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Mirum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum Pharmaceuticals$521.31M12.04-$23.36M-$15.47N/A
Ultragenyx Pharmaceutical$673M2.50-$575M-$5.19N/A

Summary

Mirum Pharmaceuticals beats Ultragenyx Pharmaceutical on 8 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Grifols?

Grifols (NASDAQ:GRFS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

Grifols has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Grifols currently has a consensus target price of $9.00, indicating a potential upside of 10.38%. Ultragenyx Pharmaceutical has a consensus target price of $29.79, indicating a potential upside of 80.71%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 0 mentions for Grifols. Ultragenyx Pharmaceutical's average media sentiment score of 0.34 beat Grifols' score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Overall Sentiment
Grifols Neutral
Ultragenyx Pharmaceutical Neutral

Grifols has a net margin of 5.54% compared to Ultragenyx Pharmaceutical's net margin of -71.78%. Grifols' return on equity of 6.21% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Grifols5.54% 6.21% 2.39%
Ultragenyx Pharmaceutical -71.78%N/A -39.70%

Grifols has higher revenue and earnings than Ultragenyx Pharmaceutical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$8.51B0.65$454.82MN/AN/A
Ultragenyx Pharmaceutical$673M2.50-$575M-$5.19N/A

Summary

Ultragenyx Pharmaceutical beats Grifols on 9 of the 15 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RARE vs. The Competition

MetricUltragenyx PharmaceuticalBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.62B$4.07B$7.76B$11.71B
Dividend YieldN/A3.63%2.47%4.68%
P/E Ratio-3.1823.4832.5328.82
Price / Sales2.5014.847.995.37
Price / CashN/A22.9521.0521.90
Price / Book-4.474.004.263.50
Net Income-$575M-$24.08M$3.51B$394.12M
1 Month Performance3.55%-13.57%-10.58%-12.04%
1 Year Performance-50.92%-7.97%-4.78%-11.42%

Ultragenyx Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RARE
Ultragenyx Pharmaceutical
2.6161 of 5 stars
$16.49
-4.3%
$29.79
+80.7%
-47.1%$1.62B$673MN/A1,371
IBRX
ImmunityBio
1.7317 of 5 stars
$5.98
-0.7%
$16.00
+167.6%
+197.8%$6.46B$113.29MN/A691
LGND
Ligand Pharmaceuticals
3.7867 of 5 stars
$301.71
-2.3%
$355.38
+17.8%
+44.1%$6.33B$268.09M134.6947
CGON
CG Oncology
3.3896 of 5 stars
$84.78
+14.0%
$88.11
+3.9%
+95.2%$6.27B$4.04MN/A142
MIRM
Mirum Pharmaceuticals
2.525 of 5 stars
$91.58
-2.6%
$155.56
+69.9%
+39.0%$6.09B$521.31MN/A433

Related Companies and Tools


This page (NASDAQ:RARE) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners